Search results

Skip to results

Type

Status

Last updated

Showing 61 to 75 of 104 results for melanoma

  1. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued [GID-TA10836]

    Technology appraisal guidance
    Discontinued

  2. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued [GID-TAG440]

    Technology appraisal guidance
    Discontinued

  3. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued [GID-TA10499]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    Awaiting development [GID-TA11586] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued [GID-TA10354]

    Technology appraisal guidance
    Discontinued

  6. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued [GID-TA10213]

    Technology appraisal guidance
    Discontinued

  7. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued [GID-TA10074]

    Technology appraisal guidance
    Discontinued

  8. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued [GID-TA10484]

    Technology appraisal guidance
    Discontinued

  9. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued [GID-TA10627]

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued [GID-TA10543]

    Technology appraisal guidance
    Discontinued

  11. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  12. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    with expert review, but it is not always possible to distinguish Spitzoid melanoma from benign Spitzoid melanocytic lesions. Current...

    Research recommendation
    Published
    4 August 2022

  13. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development [GID-TA11276] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Endoscopic radical inguinal lymphadenectomy (IPG398)

    Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.

    Interventional procedures guidance
    Published
    22 June 2011
    View recommendations

    Sections for IPG398

  15. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904